Metered-dose inhalers that use potent greenhouse gases to propel medicines into the lungs of people with cystic fibrosis (CF)…
Articles by Steve Bryson, PhD
At least three months of Kaftrio treatment reduced liver stiffness, an indicator of liver fibrosis, in school-age children and adolescents…
Long-term Trikafta treatment led to improved lung function, fewer respiratory symptoms, and lower sweat chloride levels — elevated…
The European Commission has approved a label expansion for Kaftrio in combination with Kalydeco (ivacaftor) to treat…
Evidence of immune dysfunction — elevated levels of immune cells and immune-related molecules — were found in the lungs of…
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to Porosome Therapeutics’ new treatment strategy for…
Nearly 80% of men with cystic fibrosis (CF) who underwent fertility treatment due to a lack of sperm became…
Prenatal Trikafta treatment of three fetuses with cystic fibrosis (CF) for an intestinal blockage called meconium ileus resulted…
The U.S. Food and Drug Administration (FDA) has expanded the approval of Trikafta for people with cystic fibrosis…
Infants with cystic fibrosis (CF) have alterations to the nasal microbiome — the community of microbes that live in…